X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs NATCO PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD NATCO PHARMA BIOCON LTD/
NATCO PHARMA
 
P/E (TTM) x 80.5 16.0 503.7% View Chart
P/BV x 6.8 17.2 39.6% View Chart
Dividend Yield % 0.2 0.7 25.6%  

Financials

 BIOCON LTD   NATCO PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
NATCO PHARMA
Mar-14
BIOCON LTD/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188877 135.5%   
Low Rs305424 72.0%   
Sales per share (Unadj.) Rs68.7223.4 30.8%  
Earnings per share (Unadj.) Rs7.631.1 24.3%  
Cash flow per share (Unadj.) Rs14.040.3 34.7%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.10.8 17.4%  
Book value per share (Unadj.) Rs86.3219.5 39.3%  
Shares outstanding (eoy) m600.0033.07 1,814.3%   
Bonus/Rights/Conversions ISPA-  
Price / Sales ratio x10.92.9 373.2%   
Avg P/E ratio x98.920.9 472.3%  
P/CF ratio (eoy) x53.416.1 330.9%  
Price / Book Value ratio x8.63.0 291.8%  
Dividend payout %13.216.1 82.3%   
Avg Mkt Cap Rs m447,90021,504 2,082.9%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,3111,128 825.7%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,2347,389 558.1%  
Other income Rs m2,062167 1,234.0%   
Total revenues Rs m43,2967,556 573.0%   
Gross profit Rs m8,2911,793 462.3%  
Depreciation Rs m3,851304 1,265.1%   
Interest Rs m615366 167.9%   
Profit before tax Rs m5,8871,290 456.4%   
Minority Interest Rs m21346 460.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569309 508.3%   
Profit after tax Rs m4,5311,027 441.0%  
Gross profit margin %20.124.3 82.8%  
Effective tax rate %26.723.9 111.4%   
Net profit margin %11.013.9 79.0%  
BALANCE SHEET DATA
Current assets Rs m41,4863,681 1,126.9%   
Current liabilities Rs m21,4133,123 685.7%   
Net working cap to sales %48.77.6 644.0%  
Current ratio x1.91.2 164.3%  
Inventory Days Days6489 71.5%  
Debtors Days Days9459 160.5%  
Net fixed assets Rs m50,6617,685 659.2%   
Share capital Rs m3,000331 907.2%   
"Free" reserves Rs m48,8086,670 731.8%   
Net worth Rs m51,8087,259 713.7%   
Long term debt Rs m17,898955 1,874.3%   
Total assets Rs m99,89711,957 835.5%  
Interest coverage x10.64.5 233.8%   
Debt to equity ratio x0.30.1 262.6%  
Sales to assets ratio x0.40.6 66.8%   
Return on assets %5.211.7 44.2%  
Return on equity %8.714.2 61.8%  
Return on capital %9.620.7 46.5%  
Exports to sales %039.4 0.0%   
Imports to sales %05.7 0.0%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs mNA421 0.0%   
Fx inflow Rs m12,0583,445 350.0%   
Fx outflow Rs m7,348703 1,045.5%   
Net fx Rs m4,7102,743 171.7%   
CASH FLOW
From Operations Rs m6,6211,440 459.7%  
From Investments Rs m-6,840-1,089 628.0%  
From Financial Activity Rs m-2,397-353 679.6%  
Net Cashflow Rs m-2,612-1 175,302.0%  

Share Holding

Indian Promoters % 40.4 52.0 77.6%  
Foreign collaborators % 20.6 1.5 1,401.4%  
Indian inst/Mut Fund % 8.4 7.8 107.1%  
FIIs % 10.7 16.6 64.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.0 76.5%  
Shareholders   109,995 25,395 433.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - ELDER PHARMA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS